Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
SkinJect, Inc.
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alpha Tau Medical LTD.
University of Rochester
University of Pittsburgh
Hôpital NOVO
Maastricht University Medical Center
Centre Hospitalier Universitaire Vaudois
CivaTech Oncology
University of California, Irvine
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University Hospital Augsburg
Sun Pharmaceutical Industries Limited
Case Comprehensive Cancer Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Philogen S.p.A.
McGuire Institute
Philogen S.p.A.
Jules Bordet Institute
Replimune Inc.
AI Labs Group S.L
Ohio State University Comprehensive Cancer Center
University of California, San Diego
Roswell Park Cancer Institute
Helsinki University Central Hospital
US Dermatology Partners, Phoenix
Highlight Therapeutics
Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
VA Office of Research and Development
Henry Ford Health System
Regeneron Pharmaceuticals